ID: ALA4096864

Max Phase: Preclinical

Molecular Formula: C19H21FN4O7

Molecular Weight: 436.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(F)cc3)nn2)OC(C(=O)O)=C[C@@H]1O

Standard InChI:  InChI=1S/C19H21FN4O7/c1-9(25)21-16-13(26)6-15(19(29)30)31-18(16)17(28)14(27)8-24-7-12(22-23-24)10-2-4-11(20)5-3-10/h2-7,13-14,16-18,26-28H,8H2,1H3,(H,21,25)(H,29,30)/t13-,14+,16+,17+,18+/m0/s1

Standard InChI Key:  LJPLHADKDMOZSZ-QBBQCFRVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 436.40

Molecular Weight (Monoisotopic): 436.1394

AlogP: -0.96

#Rotatable Bonds: 7

Polar Surface Area: 167.03

Molecular Species: ACID

HBA: 9

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 11

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.22

CX Basic pKa:

CX LogP: -0.97

CX LogD: -4.42

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.37

Np Likeness Score: -0.18

References

1. Guo T, Dätwyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW..  (2018)  Selective Inhibitors of Human Neuraminidase 3.,  61  (5): [PMID:29425031] [10.1021/acs.jmedchem.7b01574]

2.  (2018)  Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data